Takeda acquires selected international rights to AMAG's anaemia product Feraheme
This article was originally published in Scrip
AMAG Pharmaceuticals has licensed its anaemia product Feraheme (ferumoxytol) to Takeda for several major markets worldwide, in an alliance worth up to $280 million in upfront, development and commercial milestone payments to the US firm.
You may also be interested in...
Japanese firm in discussions with regulator as high-need novel therapy for spinocerebellar degeneration misses endpoint but shows promise in pooled analysis.
Full, planned acquisition of Tokyo-based operation will give US biotech giant a firmer foothold in key market and new platform for Otezla growth.